Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses.

Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN.

Mol Syst Biol. 2007;3:144. Epub 2007 Nov 13.

5.

PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.

Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A.

Cell Signal. 2010 Sep;22(9):1369-78. doi: 10.1016/j.cellsig.2010.05.006. Epub 2010 May 12.

6.
7.

A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling.

Hatakeyama M, Kimura S, Naka T, Kawasaki T, Yumoto N, Ichikawa M, Kim JH, Saito K, Saeki M, Shirouzu M, Yokoyama S, Konagaya A.

Biochem J. 2003 Jul 15;373(Pt 2):451-63.

8.

Robustness analysis of the detailed kinetic model of an ErbB signaling network by using dynamic sensitivity.

Masunaga H, Sugimoto Y, Magi S, Itasaki R, Okada-Hatakeyama M, Kurata H.

PLoS One. 2017 May 24;12(5):e0178250. doi: 10.1371/journal.pone.0178250. eCollection 2017.

9.
12.

EGF-induced cell migration is mediated by ERK and PI3K/AKT pathways in cultured human lens epithelial cells.

Jiang Q, Zhou C, Bi Z, Wan Y.

J Ocul Pharmacol Ther. 2006 Apr;22(2):93-102.

PMID:
16722795
13.
15.

Ligand-specific c-Fos expression emerges from the spatiotemporal control of ErbB network dynamics.

Nakakuki T, Birtwistle MR, Saeki Y, Yumoto N, Ide K, Nagashima T, Brusch L, Ogunnaike BA, Okada-Hatakeyama M, Kholodenko BN.

Cell. 2010 May 28;141(5):884-96. doi: 10.1016/j.cell.2010.03.054. Epub 2010 May 20.

16.

Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.

Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y.

Oncogene. 2010 Sep 2;29(35):4947-58. doi: 10.1038/onc.2010.240. Epub 2010 Jun 21.

PMID:
20562913
17.

A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.

Kim S, Han J, Shin I, Kil WH, Lee JE, Nam SJ.

Exp Mol Med. 2012 Aug 31;44(8):473-82. doi: 10.3858/emm.2012.44.8.054.

20.

Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells.

Fiddes RJ, Janes PW, Sivertsen SP, Sutherland RL, Musgrove EA, Daly RJ.

Oncogene. 1998 May 28;16(21):2803-13.

Supplemental Content

Support Center